| Biotechnology Industry | Healthcare Sector | Mr. Pierre Laurin B.Sc.Pharm., M.Sc. CEO | CNSX Exchange | - ISIN |
| CA Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
ChitogenX Inc., initially known as Ortho Regenerative Technologies Inc., is pivotal in the field of orthopaedic and sports medicine biologics, primarily within Canada. The company, which was founded in 2015 and later rebranded to ChitogenX Inc. in September 2022, is headquartered in Kirkland, Canada. It specializes in the research and development of innovative therapeutic soft tissue repair technologies. Their work is aimed at enhancing the success rates of orthopaedic and sports medicine surgeries through the development of novel biopolymers, positioning ChitogenX Inc. as a leader in orthopaedic biologics R&D.
Ortho-R: ChitogenX's flagship product, Ortho-R, is a biopolymer specifically designed for rotator cuff repair. This innovation targets one of the most common injuries within the field of sports medicine and orthopaedics, providing a novel approach to enhance the healing process. The technology behind Ortho-R aims at improving the integration and repair of the rotator cuff, which could significantly improve outcomes for patients undergoing such surgeries.
Ortho-M: Another groundbreaking product from ChitogenX Inc. is Ortho-M, a biopolymer developed for meniscus repair. Like Ortho-R, Ortho-M employs cutting-edge biopolymer technology to advance the healing of meniscal tears, which are prevalent in both sporting and non-sporting populations. This product stands out for its focus on enhancing the body's natural healing capacity, potentially leading to better surgical outcomes and faster recovery times for patients facing meniscus-related issues.